PTHS - Pelthos Therapeutics Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

PTHS

PELTHOS THERAPEUTICS INC.

AMEX

$25.51

▼ DOWN 4.31% (-1.15)

KEY STATISTICS

Market Cap$88.66 M

52w High$37.50

52w Low$18.19

Dividend Yield—

Frequency—

P/E-1.54

Volume20.80K

Shares Out.3.48M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Scott Plesha

ABOUT

SECTOR

Healthcare

WENT PUBLIC

February 16, 2024

METHOD OF GOING PUBLIC

SPAC

FULL TIME EMPLOYEES

PRICE TARGET

Target High$64.00

Target Low$45.00

Target Median$55.00

Target Consensus$54.67

UPCOMING EARNINGS

DateNov 12, 2026

DayThursday

Rev. Est.$17.97M

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-07-02	Reverse	1:10

PRICE

$25.51 ▼ DOWN 4.31% (−$1.15)

OVERLAYS

About Pelthos Therapeutics Inc.

https://pelthos.com ↗

Pelthos Therapeutics Inc., founded in 2002 in Durham, NC, develops and commercializes treatments like ZELSUVMI for molluscum contagiosum and proprietary nitric oxide-based therapies to address unmet patient needs.

INDUSTRY

Biotechnology

A PRODUCT PELTHOS THERAPEUTICS INC. IS KNOWN FOR

ZELSUVMI™ (berdazimer) topical gel, 10.3%

ZELSUVMI™ is the FDA-approved, first and only at-home topical gel for molluscum contagiosum in patients aged one year and older, developed by Pelthos Therapeutics, with a focus on its commercial launch and growth.